

aXichem - Entering the Commercial Phase

Redeye returns with an update of aXichem following the Q2'21 report and has reviewed the case in detail. We see a good risk/reward as the company is now entering the commercial phase and have, in turn, increased our Base Case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

aXichem - Entering the Commercial Phase